Fistular onion stalk extract exhibits anti‑atherosclerotic effects in rats

He,Benhong; Hao,Jianjun; Sheng,Weiwei; Xiang,Yuancai; Zhang,Jiemeia; Zhu,Hao; Tian,Jingcheng; Zhu,Xu; Feng,Yunxia; Xia,Hao

doi:10.3892/etm.2014.1790

Fistular onion stalk extract exhibits anti‑atherosclerotic effects in rats

Authors:
- Benhong He
- Jianjun Hao
- Weiwei Sheng
- Yuancai Xiang
- Jiemeia Zhang
- Hao Zhu
- Jingcheng Tian
- Xu Zhu
- Yunxia Feng
- Hao Xia
View Affiliations

Affiliations: Department of Cardiovascular Medicine, Lichuan Hospital of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Lichuan, Hubei 445418, P.R. China, Department of Cardiovascular Medicine, Wuhan No.1 Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Cardiovascular Medicine, The Central Hospital of Enshi Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei 445000, P.R. China, Department of Cardiovascular Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 18, 2014 https://doi.org/10.3892/etm.2014.1790
Pages: 785-792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fistular onion stalk is used as a traditional herbal medicine, and its extract exhibits certain beneficial effects on cardiovascular disease. In this study, the effects of fistular onion stalk extract on the pathological features, circulating inflammatory cytokines, local renin‑angiotensin‑aldosterone system (RAAS) and signaling pathway activities were examined using an in vivo model of atherosclerosis. Atherosclerosis of the aorta was induced by loading Sprague Dawley rats with a high‑fat diet and vitamin D2. Fistular onion stalk extract administration began five weeks after the induction of atherosclerosis and continued for 12 weeks. Rats treated with fistular onion stalk extract showed a significant reduction in the pathological region compared with the vehicle‑treated controls. Inhibition of atherosclerosis was associated with preservation of the vascular wall and immune cell infiltration. The extract also reduced the levels of the local inflammatory cytokines interleukin (IL)‑1β, IL‑6, monocyte chemoattractant protein‑1 and tumor necrosis factor‑α. Furthermore, the extract downregulated the local activity of the RAAS. In addition, extract treatment inhibited several inflammatory signaling pathways by preventing phosphorylation, including the nuclear factor κB, Janus kinase/signal transducers and activators of transcription and mitogen‑activated protein kinase pathways. These data indicate that fistular onion stalk extract may be useful for the attenuation of atherosclerosis, and the mechanism includes the regulation of the local inflammatory response.

View Figures

View References

1	Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA and Jukema JW: Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr Pharm Des. 13:1039–1052. 2007. View Article : Google Scholar : PubMed/NCBI
2	Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 125:e2–e220. 2012. View Article : Google Scholar : PubMed/NCBI
3	Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 8:802–815. 2008. View Article : Google Scholar : PubMed/NCBI
4	Koh KK: Combination treatment to prevent atherosclerosis. Hypertension. 54:e10–e11. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tian J, Gu X, Sun Y, et al: Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord. 12:702012. View Article : Google Scholar : PubMed/NCBI
6	Hoffmann H, Frieler K, Schlattmann P, Hamm B and Dewey M: Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol. 20:2824–2833. 2010. View Article : Google Scholar
7	Ross R and Harker L: Hyperlipidemia and atherosclerosis. Science. 193:1094–1100. 1976. View Article : Google Scholar : PubMed/NCBI
8	Inadera H and Hamazaki T: Cholesterol controversy: cutoff point of low-density lipoprotein cholesterol level in Guidelines by Japan Atherosclerosis Society. Nihon Eiseigaku Zasshi. 65:506–515. 2010.(In Japanese).
9	Ravnskov U: High cholesterol level may protect against infections and probably also atherosclerosis. Lakartidningen. 101:1215–1217; discussion 1218, 1221–1222. 2004.(In Swedish).
10	Nishizawa Y, Shoji T, Ishimura E, Inaba M and Morii H: Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis. 38(4 Suppl 1): S4–S7. 2001. View Article : Google Scholar : PubMed/NCBI
11	Liuzzo G: Atherosclerosis: an inflammatory disease. Rays. 26:221–230. 2001.
12	Navab M, Gharavi N and Watson AD: Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care. 11:459–464. 2008. View Article : Google Scholar
13	Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V and McNamara CA: Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res. 110:889–900. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gerrity RG, Naito HK, Richardson M and Schwartz CJ: Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol. 95:775–792. 1979.PubMed/NCBI
15	Gerszten RE, Mach F, Sauty A, Rosenzweig A and Luster AD: Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med. 136:87–92. 2000. View Article : Google Scholar
16	Frieri M: Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep. 12:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
17	Takahashi M: Inflammatory cytokines in the pathogenesis of atherosclerosis. Nihon Rinsho. 69:30–33. 2011.(In Japanese).
18	Ait-Oufella H, Taleb S, Mallat Z and Tedgui A: Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 31:969–979. 2011. View Article : Google Scholar : PubMed/NCBI
19	Morris JB, Olzinski AR, Bernard RE, et al: p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol. 28:265–271. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dąbek J, Kułach A and Gąsior Z: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB): a new potential therapeutic target in atherosclerosis? Pharmacol Rep. 62:778–783. 2010.
21	Ortiz-Muñoz G, Martin-Ventura JL, Hernandez-Vargas P, et al: Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol. 29:525–531. 2009.PubMed/NCBI
22	Kirii H, Niwa T, Yamada Y, et al: Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 23:656–660. 2003. View Article : Google Scholar : PubMed/NCBI
23	Egorova MO: Increased serum level of the acute inflammation phase parameter CRP and the high level of low density lipoprotein cholesterol - factors of increased risk of development of atherosclerosis and its complications (a literature review). Klin Lab Diagn. 3–6. 2002.(In Russian).
24	Olson NC, Callas PW, Hanley AJ, et al: Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 97:1032–1040. 2012.
25	Haddy N, Sass C, Droesch S, et al: IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis. 170:277–283. 2003. View Article : Google Scholar : PubMed/NCBI
26	Zaritsky JJ and Kalantar-Zadeh K: The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel? J Am Soc Nephrol. 23:189–191. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ferrario C: Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 5:301–314. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hershon KS: Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract. 17:430–440. 2011. View Article : Google Scholar : PubMed/NCBI
29	Cheng M, Wen R and Zhang CG: Supercritical fluid extraction of fistular onion stalk by carbon dioxide. Herald of Medicine. 27:213–215. 2008.(In Chinese).
30	Zhou BR, Pan Y and Zhai ZM: Fibrinogen and P-selectin expression in atherosclerosis model of Sprague Dawley rat. Chin Med J (Engl). 124:3768–3772. 2011.PubMed/NCBI
31	Fu Q, Liu J, Zhang C, et al: Separation and identification of flavonoids from fistular onion stalk (Allium fisturosum L. var. caespitosum Makino). J Huazhong Univ Sci Technolog Med Sci. 30:255–257. 2010. View Article : Google Scholar : PubMed/NCBI
32	Zhang JM, Hao JJ, Guo J, He BH and Huang H: Effects of fistular onion stalk extract on the level of NO and expression of endothelial NO synthase (eNOS) in human umbilical vein endothelium cells. Afr J Biotechnol. 10:2536–2540. 2011.
33	Fotis L, Agrogiannis G, Vlachos IS, et al: Intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early stages of atherosclerosis in a rat model. In Vivo. 26:243–250. 2012.PubMed/NCBI
34	Fan J and Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 10:63–71. 2003. View Article : Google Scholar : PubMed/NCBI
35	Libby P: Inflammation in atherosclerosis. Nature. 420:868–874. 2002. View Article : Google Scholar
36	Paoletti R, Gotto AM Jr and Hajjar DP: Inflammation in atherosclerosis and implications for therapy. Circulation. 109(23 Suppl 1): III20–III26. 2004. View Article : Google Scholar : PubMed/NCBI
37	Fukui K, Yamada H and Matsubara H: Pathophysiological role of tissue renin-angiotensin-aldosterone system (RAAS) in human atherosclerosis. Nihon Rinsho. 70:1556–1561. 2012.(In Japanese).
38	Hirata Y, Fukuda D and Sata M: Critical role of renin-angiotensin system in the pathogenesis of atherosclerosis. Nihon Rinsho. 69:55–59. 2011.(In Japanese).
39	Partigulova AS and Naumov VG: Inflammation and atherosclerosis: the role of Renin-Angiotensin system and its inhibition. Kardiologiia. 50:50–55. 2010.(In Russian).
40	Fukuda D, Enomoto S, Nagai R and Sata M: Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomed Pharmacother. 63:754–761. 2009. View Article : Google Scholar
41	Lu H, Balakrishnan A, Howatt DA, et al: Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br J Pharmacol. 165:2000–2008. 2012. View Article : Google Scholar : PubMed/NCBI
42	Monaco C, Andreakos E, Kiriakidis S, et al: Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA. 101:5634–5639. 2004. View Article : Google Scholar
43	Gareus R, Kotsaki E, Xanthoulea S, et al: Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 8:372–383. 2008. View Article : Google Scholar : PubMed/NCBI
44	Gharavi NM, Alva JA, Mouillesseaux KP, et al: Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem. 282:31460–31468. 2007. View Article : Google Scholar : PubMed/NCBI
45	O’Sullivan LA, Liongue C, Lewis RS, Stephenson SE and Ward AC: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol. 44:2497–2506. 2007.PubMed/NCBI
46	Recinos A III, LeJeune WS, Sun H, et al: Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 194:125–133. 2007. View Article : Google Scholar : PubMed/NCBI
47	Muslin AJ: MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 115:203–218. 2008. View Article : Google Scholar : PubMed/NCBI
48	Mamani-Matsuda M, Kauss T, Al-Kharrat A, et al: Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem Pharmacol. 72:1304–1310. 2006. View Article : Google Scholar
49	Schültke E, Kendall E, Kamencic H, Ghong Z, Griebel RW and Juurlink BH: Quercetin promotes functional recovery following acute spinal cord injury. J Neurotrauma. 20:583–591. 2003.PubMed/NCBI
50	Rivera L, Morón R, Sánchez M, Zarzuelo A and Galisteo M: Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring). 16:2081–2087. 2008. View Article : Google Scholar : PubMed/NCBI
51	Kleemann R, Verschuren L, Morrison M, et al: Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 218:44–52. 2011. View Article : Google Scholar : PubMed/NCBI